Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Illumina Inc (ILMN) SEC filings, offering a view into the company’s regulatory disclosures, financial reporting, and material corporate events. Illumina’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol ILMN, as noted in multiple Form 8-K filings.
Investors and analysts can use this filings feed to review Illumina’s current and historical reports, including Forms 10-K and 10-Q referenced in company press releases, as well as Form 8-K filings that detail significant events. Recent 8-Ks describe preliminary unaudited financial results, quarterly earnings announcements, and capital markets transactions such as the issuance of 4.750% notes due 2030 under an existing indenture, along with expected uses of proceeds for general corporate purposes and potential acquisitions.
Filings also outline material agreements and strategic transactions. For example, an 8-K dated June 22, 2025 describes a Stock Purchase Agreement under which Illumina will acquire Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic, subject to regulatory approvals and customary closing conditions. These documents provide details on purchase price, milestone payments, regulatory conditions, and termination provisions.
On Stock Titan, SEC filings for Illumina are paired with AI-powered summaries designed to highlight key elements of each document. Users can quickly identify important information in annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), as well as access data on registered securities and capital structure. Real-time updates from EDGAR ensure that new filings, including any future debt offerings, material agreements, or other reportable events, appear promptly, while AI-generated overviews help readers navigate complex regulatory language more efficiently.
Scott B. Ullem, a director of Illumina, Inc. (ILMN), reported on Form 4 that on 09/30/2025 he acquired 252 shares of Illumina common stock issued in lieu of cash retainer fees at an implied price of $99.1666 per share. Following the transaction he beneficially owns 8,389 shares, held directly. The filing states Mr. Ullem elected to receive 100% of his 2025 board and committee cash retainer fees in Illumina stock, with share counts determined using the quarter’s volume-weighted average closing price. The form is signed on 10/02/2025.
Illumina insider Steven Barnard, SVP and Chief Technology Officer, reported a sale of 287 shares of Common Stock on 09/05/2025 at a reported price of $98.93 per share, leaving him with 33,546 shares beneficially owned after the transaction. The Form 4 was signed by Robert Maynes on behalf of Mr. Barnard on 09/09/2025. The filing lists no derivative transactions.
Capital World Investors filed an amended Schedule 13G reporting beneficial ownership of 16,866,776 Illumina shares, representing 10.7% of the 158,300,000 shares believed to be outstanding. CWI reports sole voting power over 16,802,393 shares and sole dispositive power over 16,866,776 shares, and identifies itself as a division of Capital Research and Management Company. The filing states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of Illumina. The filing includes the issuer address, filer address, and CUSIP 452327109.
Illumina has entered into a significant Stock Purchase Agreement with Standard BioTools to acquire SomaLogic and Sengenics entities for $350 million in cash, plus potential milestone payments of up to $75 million. The deal, announced June 22, 2025, includes Standard BioTools' aptamer-based and functional proteomics business, featuring KREX and Single SOMAmer technologies.
Key transaction details:
- Purchase includes SomaLogic Inc, Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd
- Deal includes transition services and license agreements
- Closing deadline set for March 23, 2026, with three possible 3-month extensions
- $14.5 million termination fee if deal fails due to regulatory clearance issues
The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Act clearance and regulatory approvals. This strategic acquisition significantly expands Illumina's presence in the proteomics market, though the company notes several risk factors including integration challenges and market uncertainties.